Tonix Pharmaceuticals Holding Corp. annual report, FY2020

Tonix Pharmaceuticals Holding Corp. — 2020 Form 10-K

Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report; quarterly financial results are not clearly provided in the filing text. The company is a clinical-stage biopharmaceutical developer and reported no product revenue.

Financial performance and position

At year-end, cash and cash equivalents were $77.1 million; working capital was $78.2 million; total assets were $98.2 million; total liabilities were $10.5 million; and stockholders’ equity was $87.6 million. Liabilities included $1.3 million in operating lease liabilities. The filing does not report conventional funded debt. With no product sales, gross margin and operating margin are not meaningful.

Changes versus 2019

• Net loss widened by $21.8 million, while R&D expense nearly doubled, mainly due to the second fibromyalgia Phase 3 study, COVID-19 and smallpox vaccine programs, pipeline investment, and the Trigemina asset acquisition.
• G&A expense rose 36%, reflecting higher compensation, legal and patent costs, reporting costs, investor relations, and insurance.
• Operating cash use rose by $21.9 million. Financing proceeds increased substantially, primarily from common-stock and warrant transactions.
• Year-end common shares issued and outstanding increased to 206.0 million from 8.5 million in 2019. The filing reports 323.9 million shares outstanding as of March 15, 2021.

Pipeline, outlook, and risks

• Fibromyalgia: TNX-102 SL’s Phase 3 RELIEF study met its primary endpoint: pain-score difference versus placebo was −0.4 points (p=0.010). A second Phase 3 study, RALLY, was underway; management expected interim results in Q3 2021 and topline results in Q4 2021, subject to FDA agreement on the analysis plan. Half of enrollment was completed in March 2021.
• PTSD: Phase 3 RECOVERY did not meet its primary endpoint (p=0.343), and the FDA had rescinded TNX-102 SL’s Breakthrough Therapy designation. Management planned to discuss possible endpoints for PTSD and PTSD-related sleep disturbance with the FDA.
• Other programs: TNX-1800, a COVID-19 vaccine candidate, was preclinical; non-human primate testing showed neutralizing antibodies and was reported as well tolerated. TNX-1300 for cocaine intoxication was in Phase 2 and had FDA Breakthrough Therapy designation. Several other candidates remained preclinical or Phase 2-ready. All candidates were investigational and unapproved.
• Liquidity and going concern: The auditor’s report and management disclosures state that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. Management estimated year-end cash plus first-quarter 2021 equity proceeds would fund operations through March 31, 2022, but not beyond; additional financing may be needed, potentially causing further dilution or program reductions.
• Subsequent financing: January and February 2021 offerings generated approximately $36.9 million and $65.0 million in net proceeds, respectively, from issuing 50.0 million and 58.3 million shares. The company also reported subsequent ATM sales. These transactions increased liquidity but materially expanded the share count.
• Key risks and unusual items: Clinical and regulatory outcomes are uncertain; competition is intense, particularly for COVID-19 vaccines; the company relies on third-party clinical and manufacturing providers; and commercialization would require market access, reimbursement, and sales capabilities. 2020 included non-cash deemed dividends of $1.7 million in total related to preferred-stock conversion terms and warrant repricing. The company purchased vaccine-development property in Massachusetts and Montana, which had not been placed in service at year-end. It had $34.6 million of outstanding commitments for future contract research work.

Most important facts for investors to verify

1. Cash runway assumptions, expected spending, and the company’s ability to secure funding beyond March 2022.
2. RALLY trial progress, FDA agreement on the interim-analysis plan, and whether interim and topline timelines were achieved.
3. Whether RELIEF’s efficacy and safety findings can be replicated and support an FDA application.
4. FDA feedback and any revised development strategy following the negative RECOVERY primary endpoint.
5. Share-count changes, dilution from equity offerings and equity plans, and any further financing needs.
6. Contractual R&D commitments, manufacturing readiness, and costs to develop the vaccine facilities.